Inclusion criteria: The purpose of this phase II study is to find out what effects cabozantinib (XL184) has, good and/or bad, in patients whose tumors one of the following gene changes RET, ROS1, or NTRK fusion, or increased MET or AXL activity.
Sponsor/Collaborator: Memorial Sloan Kettering Cancer Center|Exelixis
Contact and Locations:
Study contact: Alexander Drilon, MD
Phone Number: 646-888-4206
Locations: https://clinicaltrials.gov/study/NCT01639508#contacts-and-locations
Mechanism of action: Cabozantinib is an oral medicine that inhibits of RET, ROS1, NTRK, MET, and AXL. In many of these cases, increased activation of the mesenchymal-epithelial transition (cMet) pathway appears to be a bypass signaling mechanism that allows cancer cells to circumvent the selective pressure from RET inhibitors.
Phases: Phase 2
NCT Number: NCT01639508
Status: Recruiting
